Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Maxim Olsson
Institution:
University of Gothenburg
Observed institution:
University of Gothenburg
ORCID:
0009-0005-9832-5536
Observed ORCID:
0009-0005-9832-5536
OpenAlex ID:
A5027511882
Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer
2024
·
Peter Larsson
, Daniella Pettersson
, et al.
·
Cell Death Discovery
·
33
PDF
Cancer stem cells are prevalent in the basal-like 2 and mesenchymal triple-negative breast cancer subtypes in vitro
2023
·
Maxim Olsson
, Peter Larsson
, et al.
·
Frontiers in Cell and Developmental Biology
·
21
PDF
Age and comorbidity in relation to treatment and survival outcomes in triple-negative breast cancer: A Swedish nationwide registry-based study
2025
·
Jenny Nyqvist-Streng
, Josef Somi
, et al.
·
Journal of Geriatric Oncology
·
9
PDF
Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers
2024
·
Peter Larsson
, Maxim Olsson
, et al.
·
Scientific Reports
·
5
PDF
Integrated transcriptomics- and structure-based drug repositioning identifies drugs with proteasome inhibitor properties
2024
·
Peter Larsson
, Maria Cristina De Rosa
, et al.
·
Scientific Reports
·
3
PDF
Retrospective study of comparable survival after neoadjuvant versus adjuvant chemotherapy in cT1-2N0M0 triple-negative breast cancer
2026
·
Maxim Olsson
, Slavica Janeva
, et al.
·
Breast Cancer Research and Treatment
·
1
PDF
Abstract P4-08-17: Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer
2023
·
Peter Larsson
, Daniella Pettersson
, et al.
·
Cancer Research
·
1
Show more works
View as search
Works count:
7
Citation count:
73
H-index:
4
I10-index:
2
Year
Topic
Type